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Abstract  
Epigenome regulates gene expression to determine cell fate, and accumulation of 
epigenomic aberrations leads to diseases, including cancer. NCD38 inhibits lysine-specific 
demethylase-1 (LSD1), a histone demethylase targeting H3K4me1 and H3K4me2, but not 
H3K4me3. In this study, we conjugated NCD38 with a potent small molecule called pyrrole 
(Py) imidazole (Im) polyamide, to analyze whether targets of the inhibitor could be 
regulated in a sequence-specific manner. We synthesized two conjugates using β-Ala (β) as 
a linker, i.e., NCD38-β-β-Py-Py-Py-Py (NCD38-β2P4) recognizing WWWWWW sequence, 
and NCD38-β-β-Py-Im-Py-Py (NCD38-β2PIPP) recognizing WWCGWW sequence. When 
RKO cells were treated with NCD38, H3K4me2 levels increased in 103 regions with 
significant activation of nearby genes (P=0.03), whereas H3K4me3 levels were not 
obviously increased. H3K27ac levels were also increased in 458 regions with significant 
activation of nearby genes (P=3×10-10), and these activated regions frequently included 
GC-rich sequences, but less frequently include AT-rich sequences (P=2×10-8) or 
WWCGWW sequences (P=3×10-13). When treated with NCD38-β2P4, 234 regions showed 
increased H3K27ac levels with significant activation of nearby genes (P=2×10-11), 
including significantly fewer GC-rich sequences (P<1×10-15) and significantly more AT-rich 
sequences (P<1×10-15) compared with NCD38 treatment. When treated with NCD38-β2PIPP, 
82 regions showed increased H3K27ac levels, including significantly fewer GC-rich 
sequences (P<1×10-15) and fewer AT-rich sequences (P=0.01), but significantly more 
WWCGWW sequences (P=0.0002) compared with NCD38 treatment. These indicated that 
target regions of epigenomic inhibitors could be modified in a sequence-specific manner 
and that conjugation of Py-Im polyamides may be useful for this purpose.  
 
Keywords: epigenome, histone modification, lysine-specific demethylase-1 inhibitor, 
pyrrole imidazole polyamide  
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1. Introduction  
Epigenetic modifications, e.g., DNA methylation and histone modification, have been 
identified as key epigenetic alterations that regulate gene expression; hence, their 
dysregulation is often associated with substantial diseases [1]. Cancer is known to arise 
through accumulation of epigenetic and genetic aberrations, and many tumor-suppressor 
genes are epigenetically inactivated in cancer, leading to tumor progression, invasion, and 
metastasis [2-4].  
 
For modifications at histone tails, methylation at the lysine 4 residue of histone H3 
(H3K4me) reflects transcriptional competency, whereas those at lysines 9 and 27 (H3K9me 
and H3K27me, respectively) are components of the repressive chromatin structure [5]. High 
levels of H3K4 trimethylation (H3K4me3) or H3K27 acetylation (H3K27ac) at the 
promoters are implicated in transcriptional activation, whereas H3K27 trimethylation 
(H3K27me3) is correlated with gene repression and silencing [6]. The establishment of 
appropriate histone modification patterns is essential for normal development and tissue 
differentiation, whereas dysregulation of these modulators and aberrations of histone 
modifications are associated with cancer development [7, 8].  
 
Lysine-specific demethylase-1 (LSD1) was the first histone demethylase enzyme to be 
identified for the selective demethylation of H3K4 monomethylation (H3K4me1) and 
dimethylation (H3K4me2), but not H3K4me3 [9]. LSD1 suppresses the expression of genes 
through flavin adenine dinucleotide (FAD)-dependent enzymatic oxidation processes [10]. 
In addition, LSD1 has been reported to be aberrantly upregulated in many human cancer 
types, such as prostate, breast, and lung cancer as well as neuroblastoma and leukemia 
[11-15]. Suzuki and colleagues recently developed the potent LSD1 inhibitor NCD38 [16, 
17], which consists of a lysine moiety for enzyme selectivity and a 
trans-phenylcyclopropylamine for FAD alkylation [18, 19]. NCD38 reportedly inhibits the 
cellular growth of human leukemia, lung cancer and glioma stem cells and alters the 
genome-wide chromatin status [17, 20, 21]. Although over 170 anticancer drugs have been 
approved by the US Food and Drug Administration (FDA), only six agents targeting 
epigenetic processes have been approved, including two DNA methyltransferase (DNMT) 
inhibitors (azacytidine and decitabine) and four histone deacetylase (HDAC) inhibitors 
(vorinostat, romidepsin, belinostat, and panobinostat) [22, 23]. These agents, however, 
reprogram the epigenome broadly and randomly; thus, unfavorable side effects can occur, 
along with the antitumor effects [24, 25]. A number of epigenetic agents are under 
development or in clinical trials, including inhibitors against histone methylases and 
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demethylases in addition to DNMT and HDAC inhibitors to obtain better efficacy and low 
toxicity. Another approach is the development of precisely tunable small molecules 
possessing both the ability for recognition of selective genomic regions and for altering 
epigenetic modifications. Pyrrole (Py) imidazole (Im) polyamide is a cell-permeable small 
molecule which binds the minor groove of double strand DNA (dsDNA) in 2:1 ligand to 
DNA stoichiometries with the following rules. Since Py and Im recognizes A/C/T and G, 
respectively, Py/Py pair and Im/Py pair selectively binds to A/T pair and G/C pair in 
dsDNA, respectively [26-28]. β-Ala (β) behaves like Py; Py/β pair also selectively binds to 
A/T pair in dsDNA. Py-Im polyamide reportedly acts as an artificial gene silencer with 
site-selective regulation by interfering with the interactions between transcription factors 
and their DNA binding sites [29-32]. Moreover, conjugation of Py-Im polyamide with a 
functional molecule can confer the functional molecule with 
sequence selectivity and nuclear accumulation, as is observed for DNA alkylating agents 
and fluorophores, resulting in unique bioactivities and tools [28, 33, 34].  
In this study, we applied the technologies of Py-Im polyamides to activate genomic regions 
in a sequence-specific manner by conjugation with an epigenetic inhibitor. We conjugated 
NCD38 with two different polyamides, and analyzed region-selective activation by 
genome-wide methods 
 
Results  
ChIP-seq and RNA-seq analyses of NCD38-treated cells  
Initially, we carried out genome-wide analysis for histone modification alterations induced 
by the LSD1 inhibitor NCD38 (Figure 1A). We performed ChIP-seq analysis for H3K4me2, 
H3K4me3, and H3K27ac, and RNA-seq analysis for RKO cells treated with NCD38 for 30 
days. Although H3K4me3 levels were barely increased (three regions only), 103 and 458 
regions showed more than 3-fold increases in H3K4me2 and H3K27ac levels, respectively, 
in NCD38-treated cells compared with DMSO-treated cells (Figure 1B). RNA-seq analysis 
revealed that the expression levels of genes nearest to the ChIP-seq peaks of H3K4me2 and 
H3K27ac were significantly increased in NCD38-treated cells compared with 
DMSO-treated cells (P=0.03 and P=3×10-10, respectively). These findings indicated that 
NCD38 treatment could increase H3K4me2 and H3K27ac levels, resulting in upregulation 
of genes around the activated regions.  
 
GC-rich regions preferentially activated by NCD38  
Next, we analyzed features of activated regions using 458 H3K27ac-increased regions, 
since H3K27ac is a common active mark for promoter (i.e., H3K4me3 positive) and 
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enhancer (i.e., H3K4me2-positive but H3K4me3-negative) regions. About half of the 
regions (228/458, 49.8%) were located on promoter regions, whereas 47 and 183 regions 
were distributed in enhancers and other regions, respectively (Figure 2A). Genes nearest to 
these H3K27ac peaks included 417 (promoter), 78 (enhancer), and 327 genes (other), and 
their expression levels were significantly increased (P=9×10-5, P=0.02, and P=9×10-8, 
respectively), compared with those of DMSO-treated cells (Figure 2B).  
 
Next, we analyzed the appearance of 4- and 6-bp DNA sequences within 100 bp from the 
center of the increased H3K27ac peaks. In good agreement with the preferential activation 
of promoter regions by NCD38 treatment, the top 10 sequences showed high GC contents, 
78% for 4-bp sequences and 75% for 6-bp sequences on average (Figure 3A and 3B). In 
contrast, AT-rich sequences (P=2×10-8), or sequences including WCGW such as 
WWCGWW (P=3×10-13), appeared significantly less frequently (where W means A or T) 
(Figure 3C). We then performed de novo motif analysis to analyze the motifs significantly 
enriched around the H3K27ac-increased peaks. The top four significant motifs were E2F4, 
IRF8, E2F7, and IRF4 (P=2×10-47, P=1×10-45, P=2×10-41, and P=2×10-27, respectively), which 
were all GC-rich sequences (Figure 4A and 4B). Consistent with these findings, RNA-seq 
analysis revealed that the expression levels of genes nearest to these motifs with increased 
H3K27ac levels were significantly upregulated by NCD38 (P=3×10-71, P=4×10-71, P=1×10-70, 
and P=9×10-72, respectively; Figure 4C), e.g. DLGAP5 activated by increase of H3K27ac at 
enhancers with E2F4 motif (Figure 4D and 4E) .  
 
ChIP-seq and RNA-seq analyses of NCD38-β2P4-treated cells  
Since regions containing AT-rich or WWCGWW sequences were less frequently activated 
by NCD38 treatment, we developed hybrid molecules containing NCD38 and Py-Im 
polyamides recognizing AT-rich and WWCGWW sequences, to analyze whether these less 
frequently activated regions could be targeted. First, a Py-Im polyamide Py-Py-Py-Py (P4) 
was conjugated with NCD38 with the dipeptide of β-alanine inserted as a linker, to develop 
NCD38-β-β-Py-Py-Py-Py (NCD38-β2P4) (Figure 5A). The cell permeability and nuclear 
localization of the Py-Im polyamide were confirmed using P4 conjugated with FITC 
(Supplementary Figure S1). Specific recognition of WWWWWW sequence by 
NCD38-β2P4 was confirmed; NCD38-β2P4 selectively bound to oligo DNA with 
WWWWWW sequence, but not to that with GWWWWG or WWCGWW (Supplementary 
Figure S2). The inhibitory activity of NCD38-β2P4 against histone demethylase LSD1 was 
confirmed to be similar to the parental NCD38 (Supplementary Figure S3A). It was also 
confirmed that both NCD38 and NCD38-β2P4 lacked inhibitory activity against HDAC 
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(Supplementary Figure S3B).  
When RKO cells were treated with NCD38-β2P4 for 30 days, fewer regions (234) showed 
more than 3-fold increases in H3K27ac levels compared with 458 regions by NCD38 
treatment (Figure 5B). RNA-seq analysis revealed that the expression levels of genes 
nearest to the H3K27ac-increased peaks were significantly increased in 
NCD38-β2P4-treated cells compared with DMSO-treated cells (P=2×10-11). All of the 234 
regions were distributed in non-promoter regions, including five enhancers and 229 other 
regions (Figure 6A and 6B), and there was no overlap of activated regions between NCD38 
and NCD38-β2P4 treatment. Genes nearest to these H3K27ac peaks were upregulated 
(P=0.053 and P=9×10-10, respectively) compared with DMSO-treated cells. For fear that 
these activation might be perhaps due to the effect of Py-Im polyamide itself, we treated 
RKO cells with P4 without conjugation of NCD38 for 30 days, and analyzed histone 
modification by ChIP-seq. Among the 234 regions with >3-fold increase of H3K27ac levels 
after 30-day treatment with the conjugate, none of them showed >3-fold or >1.5-fold 
increase after treatment with P4 (Supplementary Figures S4 and S5).  
 
AT-rich regions preferentially activated by NCD38-β2P4  
We next investigated whether NCD38-β2P4 could preferentially target AT-rich regions. We 
analyzed the appearance of 6-bp DNA sequences within 100 bp from the center of the 
increased H3K27ac peaks. Strikingly, the top 10 sequences showed low GC contents, i.e., 
8% for 6-bp sequences with eight of 10 sequences being WWWWWW (Figure 7A). 
Compared with NCD38 treatment, the appearance of SSSSSS sequences (where S indicates 
C or G) or 6-bp sequences including five S and one W significantly decreased in 
NCD38-β2P4 treatment (P<1×10-15). On the contrary, the appearance of WWWWWW 
sequences or 6-bp sequences including five W and one S significantly increased (P<1×10-15) 
(Figure 7B). De novo motif analysis revealed that the motifs significantly enriched around 
the increased H3K27ac peaks were Zbtb3_2, Bach1, and ONECUT3 (P=1×10-14, P=6×10-14, 
and P=9×10-14, respectively), which were all AT-rich sequences (Figure 8A and 8B). 
Consistent with these findings, RNA-seq analysis revealed that the expression levels of 
genes nearest to these motifs with increased H3K27ac levels were significantly upregulated 
by NCD38-β2P4 (P=3×10-71, P=4×10-71, P=1×10-70, and P=9×10-72, respectively; Figure 8C), 
e.g. SERPINB1 activated by increase of H3K27ac at an enhancer with Zbtb3_2 motif 
(Figure 8D and 8E).  
 
ChIP-seq and RNA-seq analyses of NCD38-β2PIPP-treated cells  
Next, another 4-mer polyamide Py-Im-Py-Py (PIPP) was conjugated with NCD38 with the 
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dipeptide of β-alanine inserted as a linker, to develop NCD38-β-β-Py-Im-Py-Py 
(NCD38-β2PIPP) (Figure 9A). The cell permeability and nuclear localization of the Py-Im 
polyamide were confirmed using PIPP conjugated with FITC (Supplementary Figure S1). 
Specific recognition of WWCGWW sequence by NCD38-β2PIPP was confirmed; 
NCD38-β2PIPP selectively bound to oligo DNA with WWCGWW sequence, but not to that 
with GWCGWG, GWGCWG, WWWGCWWW, or WWWWWW (Supplementary Figure 
S2). The inhibitory activity of NCD38-β2PIPP against histone demethylase LSD1 was 
confirmed to be similar to the parental NCD38 (Supplementary Figure S3A). It was also 
confirmed that NCD38-β2PIPP lacked inhibitory activity against HDAC (Supplementary 
Figure S3B).  
When RKO cells were treated with NCD38-β2PIPP, fewer regions (97 and 82) showed 
more than 3-fold increases in H3K4me2 and H3K27ac levels compared with NCD38 
treatment (Figure 9B). The majority (89%) of 82 H3K27ac-increased regions were 
distributed in non-promoter regions, including seven enhancer regions and 66 other regions 
(Figure 10), and there was no overlap of activated regions between NCD38 and 
NCD38-β2PIPP treatment. The upregulation of genes nearest to the H3K27ac peaks at 
enhancer regions was not significantly observed (P=0.1), perhaps due to small number of 
genes analyzed (n = 10) (Figure 10B).  
 
To investigate whether NCD38-β2PIPP could preferentially target genomic regions 
containing WWCGWW, we analyzed the appearance of 6-bp DNA sequences within 100 
bp from the center of the increased H3K27ac peaks in NCD38-β2PIPP treatment (Figure 11). 
Compared with NCD38 treatment, the appearance of SSSSSS sequences or 6-bp sequences 
including five S and one W significantly and remarkably decreased in NCD38-β2PIPP 
treatment (P<1×10-15). That of WWWWWW sequences or 6-bp sequences including five W 
and one S also decreased significantly but less remarkably in NCD38-β2PIPP treatment 
(P=0.01). On the contrary, the appearance of WWCGWW sequences significantly increased 
in NCD38-β2PIPP treatment (P=0.0002) (Figure 11), which suggests that NCD38-β2PIPP 
binds dsDNA in 2:1 ligand to DNA stoichiometries (Supplementary Figure S2C). 
WWWSWW could be presumably targeted if NCD38-β2PIPP binds DNA in 1:1 ligand to 
DNA stoichiometries, but the appearance of WWWSWW sequences did not increase in 
NCD38-β2PIPP treatment (P=0.6) (Supplementary Fig. S6).  
 
RKO cells were treated with PIPP without conjugation of NCD38 for 30 days, and 
ChIP-seq analyses were performed. Among the 82 regions with >3-fold increase of 
H3K27ac levels after 30-day treatment with the conjugate, none of them showed >3-fold or 
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>1.5-fold increase after treatment with PIPP (Supplementary Figures S7 and S8), 
suggesting that activation of regions should be due to the conjugated NCD38, not the effect 
of Py-Im polyamide itself.  
 
Inhibitor treatment for shorter period  
While activation of these regions was observed in RKO cells treated with inhibitors for 30 
days, these regions were not so activated in RKO cells treated for four days (Supplementary 
Figures S9-S16). Among the 458 regions with >3-fold increase of H3K27ac levels after 
30-day treatment with NCD38, none of them showed >3-fold increase after 4-day treatment; 
11 regions with >1.5-fold increase and 447 with <1.5-fold increase. Gene activation was not 
observed after 4-day treatment, either (Supplementary Figures S9-S11). Similarly, among 
the 234 regions with >3-fold increase of H3K27ac levels after 30-day treatment with 
NCD38-β2P4, none of them showed >3-fold increase after 4-day treatment, and no gene 
activation was observed (Supplementary Figures S12-S14). Also the 82 regions with 
increase of H3K27ac levels after 30-day treatment with NCD38-β2PIPP, were not activated 
after 4-day treatment (Supplementary Figures S15 and S16).  
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Discussion  
Although epigenetic aberrations play a significant role in carcinogenesis, inhibitors of 
epigenetic modifying enzymes are under development with the goal of establishing 
epigenetic therapy. Two DNMT inhibitors and four HDAC inhibitors have been approved 
by the FDA, and inhibitors of other epigenetic enzymes are being examined in clinical trials. 
These agents, however, reprogram the epigenome broadly and randomly; thus, unfavorable 
side effects can occur, along with antitumor effects [24, 25]. We therefore applied Py-Im 
polyamides to analyze whether epigenomic status could be altered in a sequence-specific 
manner by conjugating Py-Im polyamides with an LSD1 inhibitor, NCD38. NCD38-β2P4, 
recognizing WWWWWW sequence, and NCD38-β2PIPP, recognizing WWCGWW 
sequence, epigenetically altered regions frequently including the recognition sequences.  
 
Py-Im polyamides have affinities for specific DNA sequences as strong as transcription 
factors, and these molecules can interfere with the binding of transcription factors to their 
recognition sites [29, 35, 36]. Applying the principles of these studies, we and Dervan’s 
group recently demonstrated that Py-Im polyamides recognizing DNA with CpG sequences 
inhibited the induction of DNA methylation in vitro and in cellulo [37, 38]. While these 
studies showed that Py-Im polyamides could be utilized to inhibit DNA methylation in a 
region-selective manner, the present study suggested that Py-Im polyamides could be also 
utilized for region-selective alteration of histone modification by conjugation with 
epigenetic inhibitors.  
 
Similar to our study, Sugiyama and colleagues conjugated a library of Py-Im polyamides 
with HDAC inhibitors or histone acetyl transferase activators and reported that each 
conjugate shows histone acetylation and gene activation in living cells in a different group 
of genes [39-41]. Because these conjugates are small molecules, they can easily be taken up 
through the cell membrane and localized to the nuclei [28, 38, 42]. In these previous reports, 
however, the link between epigenetically altered regions and sequences recognized by each 
Py-Im polyamide was not necessarily clear. In this study, we clearly demonstrated that 
NCD38-β2P4 and NCD38-β2PIPP preferentially modulated regions containing their 
recognizing sequences. Recently, Ansari and colleagues conjugated JQ1, a ligand of BRD4, 
with a Py-Im polyamide recognizing GAA repeats, and the conjugate successfully activated 
the repressive region with GAA repeats via recruitment of BRD4 [43]. NCD38 is an 
inhibitor of LSD1, a demethylase for H3K4me1 and H3K4me2, but not H3K4me3. NCD38 
was previously shown to target LSD1 and increase H3K4me2 level [44], and the inhibition 
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of LSD1 activity by NCD38 and its conjugates was also confirmed in this study 
(Supplementary Figure S3A). In RKO cells, H3K4me2 levels were increased in 103 regions 
by NCD38 treatment, accompanied by significant activation of nearby genes, whereas 
increased H3K4me3 levels were barely observed. Interestingly, a significant increase in 
H3K27ac levels was also observed in the present study, similar to a previous study of 
NCD38 treatment of acute myeloid leukemia cells [20]. The mechanism mediating the 
increase in H3K27ac levels following treatment with LSD1 inhibitor has not yet been fully 
clarified, and NCD38 and its conjugates did not directly inhibit HDAC activity 
(Supplementary Figure S3B). But it was suggested that formation of the Co-REST complex 
might be involved [20]. Co-REST was identified as a corepressor of the RE-1 silencing 
transcription factor REST [45]. LSD1 is a component of the repressor complex including 
HDAC1 or HDAC2, BRAF35, and Co-REST; LSD1 rapidly degrades in the absence of 
Co-REST [46-48]. Conditional deletion of LSD1 revealed a reduction in CoREST protein 
and HDAC activity, resulting in an increase of histone acetylation [49], and knockdown of 
LSD1 by siRNA also lead to an increase of histone acetylation [50]. The HDAC molecule 
in the complex may be simultaneously inhibited when LSD1 was inhibited during treatment 
with NCD38, causing H3K27ac levels to increase. Moreover, LSD1 also works on 
demethylation of H3K9 residue and the association of LSD1 with the androgen receptor has 
been demonstrated to switch its substrate specificity from H3K4me/me2 to H3K9me/me2 to 
promote transcription of target genes [51, 52]. Gene regulation by NCD38 and its 
conjugates through alteration on H3K9 modification might also be interesting in specific 
cell types. Recently, methods modifying the clustered regularly interspaced short 
palindromic repeats-Cas9 system were applied for region-selective editing of epigenomes 
[53-56]. The technique to increase the expression of a specific gene is to tether the 
dCas9-sgRNA complex to a transcriptional activator and program it to bind nearby the 
transcriptional start site of a gene of interest [57]. The catalytic domain of human 
acetyltransferase p300 was fused to the C-terminus of dCas9, which catalyzes histone H3 
lysine 27 (H3K27) acetylation at loci up to thousands of base pairs from the 
sgRNA-specified locus and results in transcriptional activation of genes [58]. Although 
Cas9-based tools have been suggested to be useful for modifying particular epigenomic 
statuses, these tools are all macromolecules that are difficult for cells to spontaneously take 
up. In contrast, our strategy to employ Py-Im polyamides and their conjugates with small 
molecule epigenetic inhibitors could be developed as cell-permeable and nuclear-accessible 
machineries. The conjugates used in this study, NCD38-β2P4 and NCD38-β2PIPP, 
recognized no longer than 6 bp, whereas more than 15 bp are considered necessary to target 
a unique region in the human genome. Long Py-Im polyamides, such as those targeting 
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more than 20 bp could be developed [59]. Short polyamides, however, could induce 
effective modification of the epigenome by binding multiple genomic regions. Multiple 
enhancer regions with the same motif for transcription factors or repeat sequences, such as 
satellite DNA sites, may be effectively targeted by conjugates of short polyamides. Thus, 
we are currently investigating the most effective polyamide length using LSD1 inhibitors 
conjugated with Py-Im polyamides of various lengths in several types of cancer cells.  
 
In summary, we conjugated NCD38 with two different Py-Im polyamides and analyzed the 
regions epigenetically altered by parental NCD38 and the two conjugates, NCD38-β2P4 and 
NCD38-β2PIPP. The altered regions showed significant enrichment of the sequences 
recognized by the two conjugates, suggesting that conjugation of Py-Im polyamides may be 
useful for region-selective alteration of epigenomic status in a sequence-specific manner.  
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Materials and Methods  
Cell culture  
The human colorectal cancer cell line RKO was purchased from the American Type Culture 
Collection (Manassas, VA, USA). RKO cells were maintained in Eagle’s minimum 
essential medium containing 10% heat-inactivated fetal bovine serum, 100 U/mL penicillin, 
and 100 μg/mL streptomycin and were grown in a humidified incubator at 37°C. Total RNA 
from RKO cells was extracted using a QIAamp DNA Micro Kit (Qiagen, Hilden, Germany) 
and RNAeasy (Qiagen).  
 
Inhibitor treatment  
RKO cells were treated with 2 μM NCD38, NCD38-β2P4, or NCD38-β2PIPP containing 
0.1% dimethylsulfoxide (DMSO) for 30 days, and none of these inhibitors were toxic to 
RKO cells at 2 μM. Medium was refreshed every 5 days, and 2 μM DMSO, NCD38, 
NCD38-β2P4, or NCD38-β2PIPP was added when the medium was refreshed, and cells were 
passaged when necessary. On day 30, treated cells were fixed with 1% formaldehyde for 
subsequent epigenomic analyses. RNA was also isolated from cells treated for 30 days for 
transcriptome analysis. RKO cells treated with 2 μM of P4 or PIPP were collected on day 30 
for epigenomic analysis, and cells treated with 2 μM DMSO, NCD38, NCD38-β2P4, or 
NCD38-β2PIPP were also collected on day 4 for epigenomic and transcriptome analyses.  
 
RNA extraction, library construction, and RNA sequencing (RNA-seq) analysis  
RNeasy Mini Kit (Qiagen) was used to extract RNA from the cells isolated on day 30 and 
day 4, following treatment with DNaseI (Qiagen). Library preparation for RNA-seq was 
performed using a TruSeq Stranded mRNA Sample Prep Kit (Illumina, San Diego, CA, 
USA) according to the manufacturer’s protocols. The RNA-seq data were submitted to the 
NCBI BioSample database (http://www.ncbi.nlm.nih.gov/biosample), and the accession 
numbers are GSM2894015 - GSM2894018 (day 30), and GSM3039396 - GSM3039399 
(day 4). TopHat was used to align sequenced reads from the RNA-seq experiment, and 
Cufflinks was used for transcript assembly. Gene expression levels were represented as 
fragments per kilobase of exon per million mapped sequence reads.  
 
Chromatin immunoprecipitation (ChIP) and library construction  
RKO cells were crosslinked with 1% formaldehyde for 10 min at room temperature. To 
obtain 0.125 M as a final concentration, 2.5 M glycine was added to 1% formaldehyde. An 
ultrasonic disrupter (BRANSON Digital Sonifier, Branson, Danbury, CT, USA) was used to 
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sonicate the crosslinked chromatin to a size of 0.2–1 kb. About 2–5 μg antibody and 20 μL 
Protein G sepharose beads were mixed in IP dilution buffer and incubated for 
approximately 6 h at 4°C. Anti-H3K4me2 (#05-1334, Merck Millipore, Billerica, MA, 
USA), anti-H3K4me3 (#ab7766, Abcam, Cambridge, UK), and anti-H3K27ac (#39159, 
Active Motif, Carlsbad, CA, USA) antibodies were used in this study. Antibody-bound 
beads were washed with IP dilution buffer and added to the sonicated-chromatin sample. 
The mixture was incubated overnight at 4°C.  
 
The molecular weight of NCD38-β2P4, C60H70N13O10+ [M+H], was calculated to be 
1144.5363, and found to be 1144.5350. The molecular weight of NCD38-β2PIPP, 
C60H69N14O10+ [M+H], was calculated to be 1145.5316, and found to be 1145.5296. 
Detailed procedures and information for conjugation of Py-Im polyamides with NCD38 will 
be provided upon request.  
 
Distribution of fluorescein isothiocyanate (FITC)-labeled Py-Im polyamides in cultured 
RKO cells  
RKO cells were seeded at a density of 1.0 × 105 cells per 35-mm dish and grown in 2 mL 
medium. After 24 h, the living cells were incubated with 500 nM of FITC-conjugated P4 or 
PIPP containing 0.1% DMSO for 3 h. After the incubation, the cells were fixed with 1% 
HCHO for 2 h on ice. Fixed cells were washed twice with PBS followed by nuclear staining 
with 1.0 μg/mL 4',6-diamidino-2-phenylindole. Cells were visualized with a BZ-X710 
fluorescence microscope (KEYENCE, Osaka, Japan).  
 
LSD1 and HDAC assay in vitro  
LSD1 and HDAC activities were assessed using an LSD1 fluorometric drug discovery kit 
(Enzo Life Sciences, New York, NY, USA) and Histone Deacetylase Activity Assay Kit 
(Abcam, Cambridge, UK) according to the manufacturer’s instructions. Ten microliters of 
reaction mixture containing LSD1 (5 ng/mL), H3K4Me2 peptide-fragments (20 μM), 
CELLestial Red (1×), horseradish peroxidase (1×), and NCD38-conjugates (1–100 μM with 
1% DMSO) were incubated at room temperature for 30 min. To assess HDAC inhibition, 
10 μL of reaction mixture containing 1 μL of crude HDAC, Fluoro-Substrate Peptide (20 
μM), HDAC assay . buffer (1×), and NCD38-conjugates (10 μM with 1% DMSO) were 
incubated at room temperature for 20 min followed by addition of 4 μL Stop Solution and 1 
μL Developer. Relative fluorescence units at 590 nm for LSD1 and 460 nm for HDAC were 
detected using a NanoDrop 3300 (Thermo Fisher Scientific, Waltham, MA, USA) with a 
white-light and UV-light source, respectively.  
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Electrophoretic Mobility Shift Assay (EMSA)  
The 16- or 18-bp dsDNA containing targeting sequences for NCD38-β2P4 and 
NCD38-β2PIPP was prepared by annealing of oligo DNA described in Supplementary 
Table S1. In a 1.5 mL tube, 1.0 μM FAM-labeled dsDNA was incubated in 10 μL reaction 
solution containing the compounds, 10 mM Tris-HCl (pH 8.0) and 1% DMSO for 1 h at 
room temperature. The resultant complexes were loaded onto a 10% polyacrylamide gel and 
separated using EMSA in 0.5 × TBE. Selective binding between each conjugates and 
dsDNA was visualized using an LAS-3000 imaging system (Fujifilm, Tokyo, Japan)  
 
Bioinformatic and statistical analyses  
Gene ontology enrichment was performed using GREAT 
(http://bejerano.stanford.edu/great/public/html/index.php). Enrichment of de novo motifs 
was performed using HOMER software (http://homer.salk.edu/homer/index.html). Gene 
expression levels and frequencies of particular sequences were compared using Student’s 
t-tests.  
 
Abbreviations 
LSD1, lysine-specific demethylase-1; Py, pyrrole; Im, imidazole; P4, Py-Py-Py-Py; PIPP, 
Py-Im-Py-Py; β-Ala, β; FAD, flavin adenine dinucleotide; FDA, US Food and Drug 
Administration; DNMT, DNA methyltransferase; HDAC, histone deacetylase; RNA-seq, 
RNA sequencing; ChIP, chromatin immunoprecipitation; ChIP-seq, ChIP sequencing; FITC, 
fluorescein isothiocyanate.  
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Figure Legends  
Figure 1. Alteration of histone modification by NCD38 treatment. (A) Chemical 
structure of the LSD1 inhibitor NCD38. (B) Heat maps showing the read densities of 
ChIP-seq within ± 5 kb around the center position of ChIP-seq peaks. Whereas increase of 
H3K4me3 level was hardly observed, 103 and 458 regions showed >3-fold increase of 
H3K4me2 and H3K27ac levels, respectively. Expression of genes nearest to the H3K4me2 
and H3K27ac peaks were significantly upregulated (P=0.03 and P=3×10-10, respectively, 
t-test).  
 
Figure 2. Distribution of H3K27ac-increased regions following NCD38 treatment. (A) 
Pie chart for the distribution of H3K27ac peaks. About half of H3K27ac-increased regions 
are distributed in promoter regions. (B) Heat maps showing read densities of H3K4me2, 
H3K4me3, and H3K27ac within ± 5 kb around H3K27ac-increased regions in promoter, 
enhancer, and other regions with > 3-fold increase. Genes nearest to the H3K27ac peaks in 
promoter, enhancer, and other regions were significantly upregulated (P=9×10-5, P=0.02, 
and P=9×10-8, respectively).  
 
Figure 3. Appearance of DNA sequences in regions activated by NCD38. Frequencies of 
appearance of 4-bp (A) and 6-bp (B) DNA sequences within 100 bp from the center of the 
increased H3K27ac peaks are shown. GC-content of top 10 4-bp sequences was as high as 
78% (A), and that of top 10 6-bp sequences were as high as 75% (B). (C) Less frequent 
appearance of AT-rich and WWCGWW sequences. Total of 4,096 6-bp sequences were 
sorted by the order of frequency of appearance, with the most frequent sequence at the top 
(#1) and the most infrequent sequence at the bottom  
(#4096). SSSSSS or 6-bp sequences including five S and one W (left) were significantly 
enriched to the upward (P<1×10-15, Kolmogorov-Smirnov test), showing that regions with 
GC-rich sequences are likely activated. WWWWWW or 6-bp sequences including five W 
and one S (middle) were also significantly enriched to the upward (P<1×10-15), but relatively 
downward compared with SSSSSS or 6-bp sequences including five S and one W 
(P=2×10-8), showing that AT-rich regions are less likely activated than GC-rich regions. 
WWCGWW (right) were significantly enriched to the downward (P=1×10-10), and 
significantly to the downward compared with SSSSSS or 6-bp sequences including five S 
and one W (P=3×10-13), showing that regions with WWCGWW sequences are unlikely 
activated.  
 
Figure 4. Enrichment of GC-rich motifs following NCD38 treatment. (A) Heat maps 
Alagarswamy.K , et al 
 
28 
 
showing read densities of H3K27ac within ± 5 kb around H3K27ac-increased regions and 
H3K27ac levels showing >1.5-fold increase. (B) De novo motif analysis. The motifs 
significantly enriched around H3K27ac-increased regions, E2F4, IRF8, E2F7, and IRF4, 
were all GC-rich sequences. (C) Expression of genes with the enriched motifs. Expression 
levels of genes nearest to the motives of E2F4, IRF8, E2F7, and IRF4, with increased 
H3K27ac levels, were significantly upregulated by NCD38. (D) Representative image of 
DLGAP5. H3K27ac level was increased at E2F4 motif site. (E) Representative RNA-seq 
results of DLGAP5. Expression of DLGAP5 was increased.  
 
Figure 5. Alterations in histone modification by NCD38-β2P4 treatment. (A) Chemical 
structure of NCD38-β2P4. A Py-Im polyamide Py-Py-Py-Py was conjugated with NCD38, 
with the dipeptide of β-alanine inserted. The conjugate recognizes  
WWWWWW sequences, and the specific binding to the sequence was confirmed (See 
Supplementary Figure S2). (B) Heat maps showing the read densities of ChIP-seq within ± 
5 kb around the center position of ChIP-seq peaks. Less number of regions showed more 
than 3-fold increases in H3K27ac levels, compared with treatment by parental NCD38 (See 
Figure 1B). Expression of genes nearest to the H3K27ac peaks were significantly 
upregulated (P=2×10 -11, t-test).  
 
Figure 6. Distribution of H3K27ac-increased regions following NCD38-β2P4 treatment. 
(A) Pie chart showing the distribution of H3K27ac peaks. All of the 234 regions were 
distributed in non-promoter regions. (B) Heat maps showing read densities of H3K4me2, 
H3K4me3, and H3K27ac within ± 5 kb around H3K27ac-increased regions in enhancers 
and other regions with > 3-fold increase. Genes nearest to the H3K27ac peaks in other 
regions were significantly upregulated (P=9×10-10), while those in enhancer regions tended 
to be upregulated (P=0.053).  
 
Figure 7. Appearance of DNA sequences in regions activated by NCD38-β2P4. (A) 
Frequencies of appearance of 6-bp sequences within 100 bp from the center of the increased 
H3K27ac peaks. The GC content of top 10 sequences was as low as 8% in average, with 8 
of 10 sequences being WWWWWW. (B) Significant recognition of AT-rich sequences by 
NCD38-β2P4. Total of 4,096 6-bp sequences were sorted by the order of frequency of 
appearance. SSSSSS or 6-bp sequences including five S and one W (the most left), or 
SSSSSS sequences (second left), were significantly enriched to the upward (P<1×10-15) by 
NCD38 treatment, but significantly downward (P<1×10-15) by NCD38-β2P4 treatment. On 
the contrary, WWWWWW or 6-bp sequences including five W and one S (second right), or 
Alagarswamy.K , et al 
 
29 
 
WWWWWW sequences (the most right), were further enriched to the upward (P<1×10-15 or 
P=3×10-8, respectively) by NCD38-β2P4 treatment, indicating that AT-rich regions were 
likely and GC-rich regions were unlikely activated by NCD38-β2P4.  
 
Figure 8. Enrichment of AT-rich motifs following NCD38-β2P4 treatment. (A) Heat 
maps showing read densities of H3K27ac within ± 5 kb around H3K27ac-increased regions 
and H3K27ac levels showing >1.5-fold increase. (B) De novo motif analysis. The motives 
significantly enriched around H3K27ac-increased regions, Zbtb3_2, Bach1, and ONECUT3, 
were all AT-rich sequences. (C) Expression of genes with enriched motifs. Expression 
levels of genes nearest to the motives of Zbtb3_2, Bach1, and ONECUT3 with increased 
H3K27ac levels, were significantly upregulated by NCD38-β2P4. (D) Representative image 
of SERPINB1. H3K27ac level was increased at Zbtb3_2 motif site. (E) Representative 
RNA-seq results of SERPINB1. Expression of SERPINB1 was increased.  
 
Figure 9. Alterations in histone modification by NCD38-β2PIPP treatment. (A) 
Chemical structure of NCD38-β2PIPP. A Py-Im polyamide Py-Im-Py-Py, was conjugated 
with NCD38, with the dipeptide of β-alanine inserted. The conjugate recognizes 
WWCGWW sequences, and the specific binding to the sequence was confirmed (See 
Supplementary Figure S2). (B) Heat maps showing the read densities of ChIP-seq within ± 
5 kb around the center position of ChIP-seq peaks. Less number of regions (97 and 82) 
showed more than 3-fold increases in H3K4me2 and H3K27ac levels, respectively, 
compared with treatment by parental NCD38 (See Figure 1B).  
Expression of genes nearest to these H3K4me2-increased and H3K27ac-increased peaks 
were not significantly upregulated.  
 
Figure 10. Distribution of the H3K27ac-increased regions following NCD38-β2PIPP 
treatment. (A) Pie chart for the distribution of H3K27ac peaks. Where 9 of the 82 
H3K27ac-increased regions (11%) were promoter regions, 73 regions (89%) were 
distributed in non-promoter regions. (B) Heat maps showing read densities of H3K4me2, 
H3K4me3, and H3K27ac within ± 5 kb around H3K27ac-increased regions with >3-fold 
increase. Among the 73 H3K27ac peaks in non-promoter regions, the majority was other 
regions.  
 
Figure 11. Significant activation of regions with WWCGWW sequences by 
NCD38-β2PIPP treatment. Total of 4,096 6-bp sequences were sorted by the 
order of frequency of appearance. SSSSSS or 6-bp sequences including five S 
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and one W (the most left), or SSSSSS sequences (second left), were significantly 
enriched to the upward (P<1×10-15) by NCD38 treatment, and these frequencies 
were significantly decreased (P<1×10-15) by NCD38-β2PIPP treatment. 
WWWWWW or 6-bp sequences including five W and one S (middle), were 
enriched to the upward (P<1×10-15) by NCD38-β2P4 treatment, and these 
frequencies were significantly decreased (P=0.01) by NCD38-β2PIPP treatment. 
On the contrary, frequencies of WWCGWW sequences were significantly 
increased (P=0.0002) by NCD38-β2PIPP treatment, indicating that the former 
sequences were more unlikely, and WWCGWW sequences were more likely 
recognized by NCD38-β2PIPP. 
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